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Clinical studies have greatly expanded efforts to recognize
the importance of gender, and more recently the role of
diabetes and obesity, as significant co-morbidities for coro-
nary artery disease (CAD) (1,2). However, renal disease,
which appears endemic in the U.S., has not received the
same attention (3). In fact, studies testing new therapies for
acute coronary syndromes may exclude patients with renal
insufficiency. The increasing prevalence of hypertension,
diabetes, and obesity among an aging population places
more patients at risk for renal failure and dialysis.
Only recently have studies suggested that patients with
renal failure have poorer outcomes in the setting of unstable
angina and myocardial infarction (MI). The seminal work
by Herzog et al. (4) was the initial observation that unveiled
the horrible prognosis faced by patients with end-stage renal
disease suffering acute MI (AMI) (4). These observations
were confirmed and extended by Chertow et al. (5). More
recently, data from the Mayo Clinic and the Veterans
Affairs Hospital at the University of San Francisco have
revealed the significant morbidity and mortality risks faced
by those with even minor renal insufficiency suffering
non–ST-elevation myocardial infarction (STEMI) and
STEMI events (6,7).
See page 1535
In this issue of the Journal, Gibson et al. (8) continue to
reveal new insights about the increased risk associated with
renal insufficiency for patients suffering AMI. What little
data existed prior to the Gibson report have suggested a
potential modest benefit from reperfusion therapy for this
population (6). Gibson et al. (8) have extended previous
observations of the pervasive adverse influence of renal
disease to patients with STEMI who received reperfusion
therapy with fibrinolytic agents. Pooled patient data in
16,710 patients from four studies (TIMI [Thrombolysis In
Myocardial Infarction] -10A, -10B, and -14, and the
InTIME-2 trial) who were followed for two years were
analyzed. Unlike many trials that evaluated the treatment of
patients with STEMI, patients in these four studies received
some form of reperfusion therapy, including all patients
with renal insufficiency. In addition, these patients received
appropriate adjunctive therapies for their MI. But despite
more appropriate treatment, mortality was still higher in
patients with renal insufficiency independent of age and
TIMI Risk Score. Previous reports (4–6), as well as data
from the National Registry of Myocardial Infarction
(NRMI) (personal communication, August 2003), have
demonstrated less frequent use of thrombolytic agents
(4%), primary percutaneous coronary intervention (3%),
aspirin, beta-blockers, angiography, and angioplasty in pa-
tients with STEMI and renal insufficiency and higher
mortality.
Although mean blood pressures on admission were nor-
mal, there was an increased history of hypertension, as well
as diabetes, in patients with severe renal disease. Nonwhite
patients were more likely to have severe renal impairment,
although Herzog has demonstrated that African ethnicity is
protective in end-stage renal disease and AMI.
The incidence of renal insufficiency was surprisingly high
in this analysis. Gibson demonstrated that over 26% of
patients had a creatinine value of1.2 mg/dl, but some 63%
had an abnormal creatinine clearance (CrCl) 90 ml/min,
with nearly 23% having moderate or severe renal insuffi-
ciency with a CrCl 60 ml/min. Data from the Mayo
Clinic suggested that over 50% of all patients admitted for
AMI had some degree of renal impairment, whereas a
Veterans Affairs study revealed that 63% of patients on
admission had a serum creatinine1.5 mg/dl, but only 33%
of all patients had “normal renal function” defined as a CrCl
55 ml/min. Previous work has demonstrated that a CrCl
of 60 to 85 cc/min may be associated with some increased
mortality risk at the time of AMI (Fig. 1) (6).
Taken together, these observations suggest that clinical
cardiologists must no longer solely rely upon serum creati-
nine as a means of estimating renal function in their patient
populations. Instead, we recommend that clinicians esti-
mate CrCl using the modified Cockcroft-Gault formula (9)
that relies on age, weight, gender, and serum creatinine:
Creatinine clearance
(140  age)  weight (kg)
Serum creatinine (mg/dl)  72
 (0.85) in women [1]
In the study by Gibson et al. (8), mortality from heart
failure increased with more severe renal insufficiency. The
incidence of intracranial hemorrhage also was increased in
patients with more severely elevated creatinine levels, but
there was only a trend noted among patients with an
increased creatinine clearance. This observation comple-
ments and concurs with previous work and further high-
lights the risks faced by patients with renal impairment
(4–7).
Gibson et al. (8) are to be commended for defining the
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independent risk of renal insufficiency and the importance
of even “mild” forms of renal disease on outcomes in
patients with STEMI. In addition, the clear design, concise
analysis, and superb writing of the study add a clear
perspective to the subject for the reader. The cohort
analyzed in their report contained only those who received
reperfusion therapy. There was no indication of diminished
efficacy of reperfusion therapy in those with renal insuffi-
ciency, but the investigators did report that patients with
severe renal insufficiency were more likely to suffer intracra-
nial hemorrhage.
What to do with patients with renal disease and STEMI?
Evidence-based data with newer pharmaceuticals and/or an
invasive strategy are lacking. Data from the Gibson et al. (8)
study suggest that even with appropriate therapy given in a
timely manner, this may not be sufficient to ameliorate
many adverse consequences on outcomes from underlying
renal insufficiency. However, if less than appropriate treat-
ment is provided in the community settings, as suggested by
NRMI data, even poorer outcomes may be expected than
demonstrated in these randomized trials.
Future clinical trials testing new or established therapies
for ischemic heart disease need to be more inclusive of
patients with renal insufficiency, especially with the high
incidence of mild, moderate, and severe renal impairment
described in the study by Gibson et al. (8). Exclusion of
patients with renal insufficiency not only precludes many
patients who potentially might benefit from newer treat-
ments, but also may limit the study population to lower-risk
patients who might not mirror those treated in clinical
practice. In the past, women and even diabetics were
excluded from trials for a variety of reasons. But we have
learned that inclusion of these groups in clinical trials has
had a salutary effect on their outcomes. Perhaps the same
will be said one day about patients with renal insufficiency.
The inclusion of patients with varying degrees of renal
insufficiency in AMI research should become a compelling
national priority as the impact of renal insufficiency on
outcome in AMI is now well established. The incidence of
renal insufficiency will rise well into the 21st century given
its association with diabetes and hypertension, both of
which are seeing dramatic increases in incidence rates. The
time has come to move beyond the attitude of “therapeutic
nihilism” toward patients with renal failure and develop
targeted strategies from well-designed research, which will
ultimately reduce the burden of risk in this population.
A word of caution is warranted as we embark upon more
research in patients with renal insufficiency. Greater utili-
zation of current therapies to treat serious clinical conditions
such as STEMI in patients with renal insufficiency may not
be enough, however, even if applied appropriately, to reduce
significantly expected adverse outcomes. Clinical efficacy of
many commonly used therapies, such as low molecular
weight heparin, IIb/IIIa platelet inhibitors, thrombolytics,
and angioplasty may be less in these patients (6,7). Newer
agents or procedures need to be developed to achieve
improved outcomes. Patients with renal insufficiency may
experience higher rates of serious adverse events as clinical
research progresses, and we may have to accept higher
adverse event rates as the offset costs of bringing newer
therapies to this population.
We may also learn that more aggressive treatment of
AMI in patients with renal insufficiency may not be the
most effective way to reduce overall morbidity and mortality.
It may be that more aggressive primary and secondary
prevention specifically targeted at this population is the only
effective means by which the overall disease burden is
reduced. Such a hypothesis has been initially advanced by
Wright et al. (6) and should be tested. At a minimum, we
need more education to highlight risk factors that lead to
renal disease, with a major emphasis on prevention through
earlier recognition and treatment of hypertension, diabetes,
and obesity.
Whatever the ultimate outcome, the study by Gibson et
al. (8) highlights the compelling need to recognize the
increased risks faced by those with renal insufficiency
suffering AMI and highlights the challenge we face in
educating the medical community on the need to better
Figure 1. In-hospital mortality related to creatinine clearance (p  0.001).
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recognize renal insufficiency in those with even mild creat-
inine elevations as a marker of worsened prognosis.
The challenge is daunting—reduce the incidence of renal
disease through education and treatment, provide adjunctive
therapies recommended for STEMI that are not affected by
the presence of renal insufficiency to appropriate patients,
and develop newer therapies that reduce mortality in this
group of patients. Gibson et al. (8) have described the
problem; the solution is up to us.
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